ConductScience.org, home

Paper19822869

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.

Iwamoto FM and 7 others. Neurology, 2009. Cited by 264 papers, by iCite.

Cite this record

ConductScience Library. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Papers, record 19822869. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19822869

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.
PubMed
Journal
Neurology
PubMed
Year
2009
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
264
iCite
Relative citation ratio, by iCite
6.54
iCite
Revised in PubMed
2022-04-09
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Iwamoto FMF M
2Abrey LEL E
3Beal KK
4Gutin PHP H
5Rosenblum MKM K
6Reuter VEV E
7DeAngelis LML M
8Lassman ABA B

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Angiogenesis InhibitorsMajor topic
Antibodies, MonoclonalMajor topic
Brain NeoplasmsMajor topic
Drug Resistance, NeoplasmMajor topic
GlioblastomaMajor topic
Adult
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Disease-Free Survival
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
Prognosis
Retrospective Studies
Salvage Therapy
Treatment Failure

Source PubMed

Download CSV of topics

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
5 R01 CA076423-09NCI NIH HHSUnited StatesR01CA076423PubMed and NIHNIH RePORTER
UO1 CA-105663-01NCI NIH HHSUnited StatesUO1CA105663PubMedNIH RePORTER
5 R01 CA121327-02NCI NIH HHSUnited StatesR01CA121327PubMed and NIHNIH RePORTER
CA92629-06NCI NIH HHSUnited StatesPubMedPubMed
2 P30 CA008748-27NCI NIH HHSUnited StatesP30CA008748PubMed and NIHNIH RePORTER
1N01 CM-62206NCI NIH HHSUnited StatesPubMedPubMed
P50CA092629NIHNIH RePORTER
U01CA105663NIHNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in20385899Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.https://conductscience.org/library/papers/20385899

Source PubMed

Download CSV of comments and corrections

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117947719Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.J Clin Oncol2007https://conductscience.org/library/papers/17947719PubMed
219332770Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.Neuro Oncol2009https://conductscience.org/library/papers/19332770PubMed
316428489Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis.Clin Cancer Res2006https://conductscience.org/library/papers/16428489PubMed
41512163Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment.Int J Radiat Oncol Biol Phys1992https://conductscience.org/library/papers/1512163PubMed
518389177Time course of imaging changes of GBM during extended bevacizumab treatment.J Neurooncol2008https://conductscience.org/library/papers/18389177PubMed
618650835Modes of resistance to anti-angiogenic therapy.Nat Rev Cancer2008https://conductscience.org/library/papers/18650835PubMed
719249680Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.Cancer Cell2009https://conductscience.org/library/papers/19249680PubMed
819114704Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.J Clin Oncol2009https://conductscience.org/library/papers/19114704PubMed
919349600Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.Neurology2009https://conductscience.org/library/papers/19349600PubMed
1012778165The biology of VEGF and its receptors.Nat Med2003https://conductscience.org/library/papers/12778165PubMed
1116636248MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.Neurology2006https://conductscience.org/library/papers/16636248PubMed
1218711427Response criteria for glioma.Nat Clin Pract Oncol2008https://conductscience.org/library/papers/18711427PubMed
1317317837Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.Clin Cancer Res2007https://conductscience.org/library/papers/17317837PubMed
1418697955High-grade glioma before and after treatment with radiation and Avastin: initial observations.Neuro Oncol2008https://conductscience.org/library/papers/18697955PubMed
1510561324Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.J Clin Oncol1999https://conductscience.org/library/papers/10561324PubMed
1618328425HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.Cancer Cell2008https://conductscience.org/library/papers/18328425PubMed
1711005565Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.Neoplasia2000https://conductscience.org/library/papers/11005565PubMed
1817222792AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.Cancer Cell2007https://conductscience.org/library/papers/17222792PubMed
192358840Response criteria for phase II studies of supratentorial malignant glioma.J Clin Oncol1990https://conductscience.org/library/papers/2358840PubMed
2012684411Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.Clin Cancer Res2003https://conductscience.org/library/papers/12684411PubMed

See all 31 referencesDownload CSV of references

Cited by182

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 264 citations.

PMIDTitleJournalYearIn PapersSource
42530690Spatial patterns of progression in reported glioblastoma cohorts after upfront chemoradiation and salvage therapy: a systematic review and meta-analysis.J Neurooncol2026https://conductscience.org/library/papers/42530690PubMed
42325608Phase 2 study of regorafenib in patients with progressive glioblastoma after failure of bevacizumab.Neurooncol Adv2026https://conductscience.org/library/papers/42325608PubMed
42028236Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.Neurooncol Adv2026https://conductscience.org/library/papers/42028236PubMed
41211508Ambient ionization mass spectrometry in brain cancer diagnosis.J Mass Spectrom Adv Clin Lab2025https://conductscience.org/library/papers/41211508PubMed
40802280Liposomal honokiol enhance the anti-tumor effect of bevacizumab in glioblastoma by inhibiting autophagy.Future Sci OA2025https://conductscience.org/library/papers/40802280PubMed
40775789Glioblastoma metabolomics: uncovering biomarkers for diagnosis, prognosis and targeted therapy.J Exp Clin Cancer Res2025https://conductscience.org/library/papers/40775789PubMed
40191237Translational Insights into Cancer-Associated Fibroblast Infiltration-Related Biomarkers in Glioblastoma and Their Clinical Prognostic Value.Int J Gen Med2025https://conductscience.org/library/papers/40191237PubMed
39925637A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma.Neurooncol Adv2025https://conductscience.org/library/papers/39925637PubMed
39775160Repeated 5-aminolevulinic acid mediated sonodynamic therapy using magnetic resonance guided focused ultrasound in rat brain tumour models.Sci Rep2025https://conductscience.org/library/papers/39775160PubMed
39001500The Use of Apparent Diffusion Coefficient Values for Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis in Glioblastoma.Cancers (Basel)2024https://conductscience.org/library/papers/39001500PubMed
38596714Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design.Neurooncol Adv2024https://conductscience.org/library/papers/38596714PubMed
38473812Intrinsic and Microenvironmental Drivers of Glioblastoma Invasion.Int J Mol Sci2024https://conductscience.org/library/papers/38473812PubMed
37684373Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial.Commun Med (Lond)2023https://conductscience.org/library/papers/37684373PubMed
37568606Advanced Magnetic Resonance Imaging in the Evaluation of Treated Glioblastoma: A Pictorial Essay.Cancers (Basel)2023https://conductscience.org/library/papers/37568606PubMed
36987739Therapeutic potential of tumor treating fields for malignant brain tumors.Cancer Rep (Hoboken)2023https://conductscience.org/library/papers/36987739PubMed
36260832NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.J Clin Oncol2023https://conductscience.org/library/papers/36260832PubMed
36059707Metabolic management of microenvironment acidity in glioblastoma.Front Oncol2022https://conductscience.org/library/papers/36059707PubMed
35583721Initial results of a phase II trial of 18F-DOPA PET-guided re-irradiation for recurrent high-grade glioma.J Neurooncol2022https://conductscience.org/library/papers/35583721PubMed
35419519The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab.Neurooncol Adv2022https://conductscience.org/library/papers/35419519PubMed
35281485Advanced Imaging Techniques for Newly Diagnosed and Recurrent Gliomas.Front Neurosci2022https://conductscience.org/library/papers/35281485PubMed

See all 182 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19822869

GET https://conductscience.org/api/papers/v1/19822869/references?page=2